Prevalence of metabolic syndrome (MetS) in Chinese subjects gradually increased with impaired glucose homeostasis: a multicenter, clinical based, cross-sectional study

BMC Public Health

Zhiguang Zhou¹  Pengcheng Zhou¹  Zhihong Che¹  Weidong Zhou¹  Gan Huang¹  Yufei Xiang¹ 

[1] Diabetes Center, 2nd Xiangya Hospital, and Institute of Metabolism and Endocrinology, Key Laboratory of Diabetes Immunology, Ministry of Education, Central South University, Changsha, Hunan, 410011, China

关键词: Impaired glucose tolerance;    Impaired fasting glucose;    Diabetes;    Metabolic syndrome;   

Others  :  1163251
DOI  :  10.1186/1471-2458-12-675

 received in 2012-02-15, accepted in 2012-08-10,  发布年份 2012

【 摘 要 】

Background

Metabolic Syndrome (MetS) is a high risk factor for Cardiovascular Diseases (CVD). We estimated to investigate how MetS prevalence by glucose homeostasis varies across different age and gender groups.

Methods

We studied 9257 Chinese subjects over the age of 15 years in two cross-sectional surveys in 2006. With oral glucose tolerance test (OGTT) test, 2341 subjects were normal glucose tolerance (NGT), and 5448 were diagnosed as having type 2 diabetes (T2D). All other 1468 subjects were considered to be impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) subjects. Diabetes was diagnosis by WHO99 criteria. We used modified NCEP-III criteria for the diagnosis of MetS.

Results

The prevalences of MetS in the male NGT, IFG/IGT and T2D groups were 25.9% (404/1559), 65.6% (769/1172), and 73.5% (2483/3376), respectively. The prevalences of MetS in the female NGT, IFG/IGT and T2D groups were 13.4% (105/782), 51.0% (151/296), and 75.4% (1563/2072), respectively. The prevalence of MetS in the male IFG/IGT group gradually decreased from 73.26% to 41.08% in subjects over the age of 30 years. The prevalence of MetS in the female IFG/IGT group gradually increased from 30% to 75% with aging.

Conclusions

The prevalence of MetS in subjects with different glucose tolerances in China was high and gradually increased with impaired glucose homeostasis both in males and females.

【 授权许可】

   
2012 Xiang et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Steinberger J, Daniels SR, Eckel RH, et al.: Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009, 119:628-647.
• [2]Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
• [3]Hunt KJ, Resendez RG, Williams K, et al.: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004, 110:1251-1257.
• [4]Chan JC, Malik V, Jia W, et al.: Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009, 301:2129-2140.
• [5]Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
• [6]Al-Lawati JA, Mohammed AJ, Al-Hinai HQ, et al.: Prevalence of the metabolic syndrome among Omani adults. Diabetes Care 2003, 26:1781-1785.
• [7]Jaber LA, Brown MB, Hammad A, et al.: The prevalence of the metabolic syndrome among arab americans. Diabetes Care 2004, 27:234-238.
• [8]Ilanne-Parikka P, Eriksson JG, Lindstrom J, et al.: Prevalence of the metabolic syndrome and its components: findings from a Finnish general population sample and the Diabetes Prevention Study cohort. Diabetes Care 2004, 27:2135-2140.
• [9]Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28:2745-2749.
• [10]Ford ES, Ajani UA, Mokdad AH: The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005, 28:878-881.
• [11]Misra A, Khurana L: Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab 2008, 93:S9-S30.
• [12]Liu J, Grundy SM, Wang W, et al.: Ethnic-specific criteria for the metabolic syndrome: evidence from China. Diabetes Care 2006, 29:1414-1416.
• [13]Gu D, Reynolds K, Wu X, et al.: Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 2005, 365:1398-1405.
• [14]Wang JJ, Hu G, Lappalainen J, et al.: Changes in features of the metabolic syndrome and incident impaired glucose regulation or type 2 diabetes in a chinese population. Diabetes Care 2005, 28:448-450.
• [15]Yang W, Lu J, Weng J, et al.: Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101.
• [16]Obesity: preventing and managing the global epidemic. Report of a WHO consultation World Health Organ Tech Rep Ser 2000, 894:1-253. i-xii
• [17]Chalmers J, MacMahon S, Mancia G, et al.: 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 1999, 21:1009-1060.
• [18]Hanefeld M, Karasik A, Koehler C, et al.: Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial. Diab Vasc Dis Res 2009, 6:32-37.
• [19]Isomaa B, Almgren P, Tuomi T, et al.: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24:683-689.
• [20]Hanefeld M, Koehler C, Gallo S, et al.: Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol 2007, 6:13. BioMed Central Full Text
• [21]Guzder RN, Gatling W, Mullee MA, et al.: Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 2006, 49:49-55.
• [22]Lorenzo C, Williams K, Hunt KJ, et al.: Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care 2006, 29:625-630.
• [23]Hawa MI, Thivolet C, Mauricio D, et al.: Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care 2009, 32:160-164.
• [24]Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356-359.
• [25]Tan CE, Ma S, Wai D, et al.: Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004, 27:1182-1186.
• [26]Muller M, Grobbee DE, den Tonkelaar I, et al.: Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005, 90:2618-2623.
• [27]Laaksonen DE, Niskanen L, Punnonen K, et al.: Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 2003, 149:601-608.